Treatment Advances

November 20, 2024

If you are an adult with relapsed/refractory precursor B-cell ALL, learn how a new FDA-approved CAR T-cell therapy may be a treatment option for you.

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

November 01, 2024

Learn about how VNX-101 can help ALL patients that are CD19 positive.

November 01, 2024

Learn how a new treatment option for acute lymphocytic leukemia, a CAR T therapy called obe-cel, can be an effective treatment.

July 15, 2024

TCR-T Therapies TSC-100 and TSC-101 were given FDA Designation in AML, ALL, and MDS.

July 03, 2024

FDA approves Blincyto for CD19-positive B-ALL in consolidation phase, offering improved survival rates and new hope for patients.